Meeting
2019 ASCO Annual Meeting
Effect of epigenetic modifier-based combinations on efficacy in patients with peripheral T-cell lymphoma (PTCL): Deciphering impact of mutations in epigenetic operations on response.
Authors
Owen A. O'Connor
Columbia University Medical Center, New York, NY
Owen A. O'Connor , Lubomir Sokol , Andrei R. Shustov , Lorenzo Falchi , Jennifer Kimberly Lue , Francesca Montanari , Jennifer Amengual , Ahmed Sawas , Chanchung Deng , Karen Khan , Alice Jacobs , Aishling Rada , Hye A. Kim , Craig R. Soderquist , David Park , Daniel Menezes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Other Lymphoma
Clinical Trial Registration Number
NCT01998035; NCT01947140
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7565)
DOI
10.1200/JCO.2019.37.15_suppl.7565
Abstract #
7565
Poster Bd #
319
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed/refractory or intolerant to available therapies.
First Author: Kristen McCullough
Poster
2021 ASCO Annual Meeting
Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).
First Author: Jia Ruan
Poster
2018 ASCO Annual Meeting
The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL).
First Author: Steven M. Horwitz
Poster
2018 ASCO Annual Meeting
Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).
First Author: Anna F. Farago